Neuromedin U — Indexed Studies

Knowledge, attitudes, and practices of patients with chronic kidney disease toward osteosarcopenia.

Yang C, Wei W, Chai W et al.

High Prevalence of Malnutrition and Sarcopenia with Inadequate Nutritional Support in Intensive Care Unit Patients: A Prospective Observational Study of Clinical Outcomes.

Ben Othman R, Cherni A, Dergaa I et al.

Risdiplam Impact in Treatment Naïve and Non-Naïve Pediatric and Adult Patients With Spinal Muscular Atrophy.

Yee POP, Ip HHN, Yu MKL et al.

Nicotinamide and Pyridoxine Supplementation Enhances Muscle Stem Cell Activity and Muscle Regeneration in Humans: A Randomized Placebo-Controlled Clinical Trial of High Force Eccentric Contraction Recovery in Healthy Young Men.

Højfeldt G, Michaud J, Damgaard A et al.

Autism spectrum disorder in children with spinal muscular atrophy type 1: Case series.

Rezende LV, Ortega AB, Do Valle DA et al.

Co-existence of Possible Sarcopenia and Dysphagia is Associated with Poor Functional Outcomes in Patients with Acute Stroke: A 1-Year Follow-up Study.

Sato Y, Abe T, Kimura Y et al.

X-linked Emery-Dreifuss muscular dystrophy caused by a novel FHL1 mutation: A case report.

Zhang H, Tang S, Zhang W et al.

Impairment of lip and tongue strength in symptomatic SMA1 patients: Results from a 4-center prospective study using the IOPI.

Colot C, Trucco F, Ruiz Chicaiza P et al.

Perceptions of Exercise Benefits and Barriers and Physical Activity Status Among Patients Undergoing Hemodialysis in Saudi Arabia.

Almaimani M, Alsolami E, Alghamdi AH et al.

Association between SARC-F as a self-report screening tool for sarcopenia and muscle strength, physical performance, daily activity, patient-reported outcomes and body composition in patients with spondyloarthritis.

Kononenko J, Bedei M, Buehring B et al.

Anabolic and catabolic responses to different modes of exercise in patients with chronic kidney disease.

Gould DW, Baker LA, Wilkinson TJ et al.

Pediatric Spinal Muscular Atrophy Patients Treated With Nusinersen: Experience From a Tertiary Referral Center in Turkey.

Öz Yıldız S, Bulut N, Alemdaroğlu-Gürbüz İ et al.

Outcomes of combination therapy with nusinersen, onasemnogene abeparvovec, and risdiplam over 3.5 years in a patient with prenatally diagnosed spinal muscular atrophy type 0: A case report.

Okubo Y, Togashi N, Morishita Y et al.

Effects of Phenolic-Rich Extra Virgin Olive Oil and Prebiotics on Sarcopenia in Older Adults: FOOP-Sarc Project.

Besora-Moreno M, Jiménez-Ten Hoevel C, Queral J et al.

First combined analysis of SMN1, SMN2, and NAIP copy numbers in Moroccan SMA patients and their correlation with disease severity.

Nmer S, Trhanint S, Sayel H et al.

Protocol for a prospective cohort study for the assessment of sarcopenia in gestational diabetes: the SiGnal-D study.

Dardano A, Daniele G, Göbl CS et al.

Impact of Home-Based Respiratory Physiotherapy in Nusinersen-Treated Patients with Spinal Muscular Atrophy.

Be'er M, Shperling L, Rochman M et al.

Hereditary Myopathy With Early Respiratory Failure: A Case Report and Review of the Literature.

Acurio K, Pacheco-Barrios N, Calisaya-Madariaga IG et al.

Effect of whole-course nutrition management on skeletal muscle mass in patients with gastric cancer undergoing neoadjuvant treatment.

Liu C, Huang H, Liu J et al.

[Diagnosis and Management of the Patient with Obesity: Position Statement of the Obesity and Sarcopenia Working Group of the Spanish Society of Rehabilitation and Physical Medicine].

Supervía M, Sainz de Murieta E, Figueroa J et al.

Weighted vest use or resistance exercise to offset muscle loss in older adults: secondary findings from the INVEST in bone health RCT.

Lynch SD, Howard M, Beavers DP et al.

Imaging spectrum and diagnostic insights in Hirayama disease: A case series.

Rajkumar I, Baskar A, Priyadarshee P et al.

Correlation Between Psoas and Diaphragmatic Ultrasound Indices for the Assessment of Sarcopenia in Patients with Inflammatory Bowel Disease: A Prospective Single-Center Study.

Palmisano CM, Dell'Aquila P, Contaldo A et al.

Transcriptomic suppression of immune and ECM stability in skeletal muscle of patients with chronic kidney disease.

Baker LA, Eastley N, Ashford RU et al.

Enhancing Patient-Centered Health Technology Assessment: A Modified Delphi Panel for PICOS Scoping in Spinal Muscular Atrophy.

Arcà E, Barlassina A, Eze A et al.

Myosteatosis and myopenia may predict oncologic outcomes in patients with rectal cancer receiving preoperative chemoradiotherapy.

Kitajima T, Okugawa Y, Shimura T et al.

Clinical and Genetic Analysis of Limb-Girdle Muscular Dystrophy Type 2F with A Novel SGCD Mutation: A Case Report.

Sakhaei A, Mohammadi-Asl J

Summary of Research: Risdiplam Treatment Following Onasemnogene Abeparvovec in Individuals with Spinal Muscular Atrophy: A Multicenter Case Series.

Svoboda MD, Kuntz N, Leon-Astudillo C et al.

Immediate and Sustained Effects of Intensive Equine-Assisted Physiotherapy Based on Neuroproprioceptive "Facilitation and Inhibition" on Psychomotor Development, Clinical Functions, Quality of Life, and Molecular Biological Indicators in Children With Spinal Muscular Atrophy: Protocol for a Crossover Randomized Controlled Trial.

Marikova K, Reissigova J, Vilimek M et al.

Clinical outcome and efficacy of nusinersen in Korean adult patients with 5q spinal muscular atrophy: Nationwide multicenter retrospective study.

Lee JM, Park HJ, Kim H et al.

Cancer Cachexia Prevalence Is Underestimated in Medical Records of Patients in a Regional Tertiary Hospital.

Colardelle Y, Daligault M, Grosjean J et al.

Effect of early intensive physical therapy on NLRP3 inflammasome activation and muscle atrophy in critical illness myopathy (PT-NLRP3-CIM): a two-centre randomized open-label study protocol.

Arellano-Pérez Ó, Americo-Da-Silva L, Valladares-Ide D et al.

Nusinersen rescues taurine deficiency in patients with type 1 Spinal Muscular Atrophy.

di Vito R, Hassan A, Nuzzo T et al.

Loss of Myonuclei and Transcriptional Activity During Diaphragm Atrophy in Critically Ill Patients.

Claassen WJ, van den Berg M, Shi ZH et al.

Microvascular pathology in the spinal cord of severe spinal muscular atrophy patients.

Allardyce H, Lanz H, Lawrence BD et al.

Safety and Efficacy of Tamoxifen in Patients with Duchenne muscular dystrophy: open Label Extension of TAMDMD Trial.

Zwingli G, Putananickal N, Schmidt S et al.

Motor Function Changes in Duchenne Muscular Dystrophy: A Case Series Using Conventional and Spinal Muscular Atrophy-Based Assessments During Viltolarsen Treatment.

Iwayama H, Numoto S, Azuma Y et al.

Body Composition in Liver Transplant Patients: Long-Term Changes and Impact on Recovery Outcomes.

Leunis S, Desloovere E, Van Criekinge H et al.

Long-Term Risk of Inflammatory Bowel Disease With Sarcopenia Status: A Large-Scale Prospective Cohort Study.

Zhang Q, Gui P, Liu S et al.

Association of growth differentiation factor-15 with muscle wasting and anemia in chronic kidney disease.

Lin TY, Chen YC, Hung SC

Hemochromatosis of unknown origin in a young adult dog.

Arends A, Koziy R, Aburto E et al.

Astrocyte targeted SMN1 gene therapy and forskolin application improves astrocyte filopodia actin defects and motor neuron synaptic dysfunction in human SMA disease pathology.

Welby E, Liu X, Wojtkiewicz M et al.

Sarcopenia, body composition, physical performance, and clinical features in Parkinson's disease: a cross-sectional comparative study.

Gomes de Luna JR, Lima DP, Gomes VC et al.

KARIs, Ghrelin Receptor Agonists With Excellent Brain Permeability, Increase Food Intake and Attenuate the Muscle Loss in Mice.

Yoon HJ, Han WH, Kim SB et al.

Treatment advances for Duchenne muscular dystrophy.

Zygmunt A, Tian C

Guidelines for Rehabilitation Interventions in Older Adults With Sarcopenia (2025 Edition).

Li Y, Wang S, Wang X et al.

Utility of Far-Field Potentials as a Biomarker of Neurodegeneration in Spinal Muscular Atrophy.

Calma AD, Pavey N, Silva CS et al.

Targeting muscle, mitochondria, and microbiome: nutritional and exercise strategies across wasting diseases and conditions.

Engelen MPKJ, van der Meij BS

Could an outcome-based agreement be operationalized using real-world data from the Canadian Neuromuscular Disease Registry? Perspectives from an expert-led assessment in spinal muscular atrophy.

Mitha A, Hodgkinson V, Vander Wyk S et al.

Corrigendum to "Learnings from a registry-based cohort study for spinal muscular atrophy disease" [Neuromuscular Disorders, Volume 59, February 2026, 106332].

Jonker CJ, Plueschke K, Breen KC et al.